250 related articles for article (PubMed ID: 8638540)
21. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Alvarez JA; Marín J; Jover JM; Fernández R; Fradejas J; Moreno M
Dis Colon Rectum; 1995 May; 38(5):535-42. PubMed ID: 7537651
[TBL] [Abstract][Full Text] [Related]
22. Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading.
Ghaderi B; Moghbel H; Daneshkhah N; Babahajian A; Sheikhesmaeili F
J Gastrointest Cancer; 2019 Sep; 50(3):525-529. PubMed ID: 29806060
[TBL] [Abstract][Full Text] [Related]
23. [Clinical usefulness of circulating tumor markers].
Ohkura H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
[TBL] [Abstract][Full Text] [Related]
24. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
25. Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer.
Gitsch G; Kainz C; Joura E; Fröhlich B; Bieglmayr C; Tatra G
Anticancer Res; 1992; 12(4):1247-9. PubMed ID: 1503417
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
27. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
28. Serum SCC-Ag in head and neck squamous cell carcinoma.
Palermo F; Carniato A; Fede A; Boccaletto F; Marchiori C
Int J Biol Markers; 1990; 5(3):118-20. PubMed ID: 2286775
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer.
Kelloniemi E; Rintala E; Finne P; Stenman UH;
Urology; 2003 Aug; 62(2):249-53. PubMed ID: 12893328
[TBL] [Abstract][Full Text] [Related]
30. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of TATI and other markers in solid tumors.
Taccone W; Mazzon W; Belli M
Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686
[TBL] [Abstract][Full Text] [Related]
32. Disappearance curves for tumor markers after resection of intrathoracic malignancies.
Yoshimasu T; Maebeya S; Suzuma T; Bessho T; Tanino H; Arimoto J; Sakurai T; Naito Y
Int J Biol Markers; 1999; 14(2):99-105. PubMed ID: 10399629
[TBL] [Abstract][Full Text] [Related]
33. Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities.
Casetta G; Piana P; Cavallini A; Vottero M; Tizzani A
Br J Urol; 1993 Jul; 72(1):60-4. PubMed ID: 8149183
[TBL] [Abstract][Full Text] [Related]
34. Human chorionic gonadotropin and CA 15-3 producing adenocarcinoma.
Uçkaya G; Ozet A; Arpaci A; Kömürcü S
Nuklearmedizin; 1998; 37(8):297-8. PubMed ID: 9868713
[TBL] [Abstract][Full Text] [Related]
35. Serum and tissue levels of CEA, TPA, CA 125 and CA 15.3 in patients with lung cancer.
Macchia V; Paduano D; Di Carlo A; Mariano A; Cecere C; Ferrante G
Int J Biol Markers; 1993; 8(4):215-20. PubMed ID: 8138661
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract.
van der Gaast A; Kirkels WJ; Blijenberg BG; Splinter TA
J Cancer Res Clin Oncol; 1992; 118(8):626-8. PubMed ID: 1517284
[TBL] [Abstract][Full Text] [Related]
37. Tumour markers and their prognostic value in adenocarcinoma of the cervix.
Ngan HY; Cheung AN; Lauder IJ; Cheng DK; Wong LC; Ma HK
Tumour Biol; 1998; 19(6):439-44. PubMed ID: 9817971
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response.
Leminen A; Alftan H; Stenman UH; Lehtovirta P
Acta Obstet Gynecol Scand; 1992 May; 71(4):293-7. PubMed ID: 1322623
[TBL] [Abstract][Full Text] [Related]
39. AFP, CEA, CA 19-9 and TPA in hepatocellular carcinoma.
Maussier ML; Valenza V; Schinco G; Galli G
Int J Biol Markers; 1990; 5(3):121-6. PubMed ID: 1704905
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of tumor markers in patients with squamous cell carcinoma in the oral cavity.
Kurokawa H; Tsuru S; Okada M; Nakamura T; Kajiyama M
Int J Oral Maxillofac Surg; 1993 Feb; 22(1):35-8. PubMed ID: 7681461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
